indium in-111
Approved
Dec 29, 1992
Indium In-111 pentetate disodium is a radioactive diagnostic indicated for use in radionuclide cisternography. Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column. Indium In 111 pentetate ( 111In-DTPA) is indicated as an imaging agent in cisternography to study the flow of cerebrospinal fluid (CSF) in the brain, to diagnose abnormalities in CSF circulation, to assess and help localize the site of CSF leakage, and to test the patency of or localize blocks in CSF shunts. — NCATS
Clinical trial activity
1 trials · 2 clinical orgs · 2 marketing orgs
Earliest trial started Jul 1, 2007 (NCT00602862)
Timeline
1990s
- Dec 29, 1992
General Electric — Earliest FDA Approval
- Dec 29, 1992
General Electric — NDA Secondary Org
- Dec 29, 1992
General Electric — NDA Organization
- Sep 27, 1994
Curium Pharma — NDA Secondary Org
Indications
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedDec 29, 1992
Chemistry & pharmacology
SMILES
[111In+3]- Mol. weight
- 221.18 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1447815 ↗
- WikipediaIndium ↗
- NCATSWJZ06C0H8L ↗
- ChEMBLCHEMBL1201078 ↗
- NCATSE9NGC49E0T ↗
Also known as
- 111in-bevacizumab
- (111)indium chloride
- 111indium trichloride
- 111indium trichloride
- (113)indium chloride
- indiclor
- indiclor
- indiclor
- indium
- indium
- indium-111 chloride
- indium-111 chloride
- indium (111in) chloride injection
- indium chloride
- indium chloride
- indium chloride
- indium chloride (111incl3)
- indium chloride (111incl3)
- indium chloride in-111
- indium chloride in-111
- indium chloride (incl3)
- indium in-111
- indium in 111 chloride
- indium in 111 chloride
- indium in 111 chloride
- indium in-111 chloride
- indium in-111 chloride
- indium in-111 chloride
- indium in-111 chloride solution
- indium in 111m chloride
- indium in 111m chloride
- indium in-111m chloride
- indium in-111m chloride
- indium trichloride
- indium trichloride, 111in-labeled
- indium trichloride (113)
- indium trichloride, 113in-labeled
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00602862 | N/A | Jul 1, 2007 | Dutch Cancer Society, Radboud University |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dutch Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2007 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Curium Pharma | For profit | NDA2 | Sep 27, 1994 |
| General Electric | For profit | NDA2 | Dec 29, 1992 |
| General Electric | For profit | NDA | Dec 29, 1992 |